Centauri Therapeutics, Sandwich, UK
www.centauritherapeutics.com/

ABX01
NOVEL LARGE MOLECULE ANTIBACTERIAL

Duel-acting Immunotherapy

Centauri Therapeutics is developing novel immunotherapies, leveraging its proprietary Alphamer™ platform which re-directs existing polyclonal antibodies to address indications of high unmet need, including hard-to-treat bacterial infections. With CARB-X support, Centauri will continue development of its lead program, ABX01. ABX01 targets drug-sensitive and multi-drug resistant (MDR) Gram-negative bacteria, including clinically-relevant strains of Enterobacteriaceae, P. aeruginosa, and A. baumannii. The novel features of this approach are: an ability to harness and re-direct pre-existing and naturally occurring effector antibodies; broad spectrum efficacy against Gram-negative bacterial infections; and direct and immune-mediated mechanism of bacterial killing

Current Development Stage: Lead Optimization

CARB-X Investment: Initial investment of up to $1.4m

Initial CARB-X Investment Date: December 1, 2019